Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Problem Tech Solves
Tech Brief
Today, 74% of American adults are living with overweight and obesity, a figure forecasted to rise to 90% by 2030. Obesity is America's underlying pandemic, and 88% of American adults are in poor metabolic health. With a general increased focus on health due to the pandemic and studies stressing the link between overweight and obesity and poor COVID-19 outcomes, access to Calibrate’s effective treatment combining GLP-1 medications with its proprietary intensive lifestyle intervention (ILI) is more important than ever. Improving metabolic health leads to sustained weight loss, thus solving the obesity crisis. But access to proper treatment has been limited by scale, the ability to obtain GLP-1 medications at an affordable cost, and the ability to effectively deliver ILI. Moreover, there are only 5,000 obesity medicine specialists in the United States for the nearly 200 million adults living with overweight and obesity. In living our mission to change the way the world treats weight, we are establishing the standard of care for obesity treatment and expanding access to ensure that safe and effective treatment for those living with overweight and obesity is available.
Tech Differentiators
Calibrate was built as a metabolic health company. Weight loss is not the goal of our treatment, rather a fundamental outcome when improving metabolic health. At the start of the program, members fill out a 150-question intake and have a 45-minute face-to-face video visit with a board-certified doctor who prescribes a clinically appropriate GLP-1 medication––that work on key underlying metabolic pathways to offer critical health improvements. Adoption rates for GLP-1s are low because getting insurance coverage is complicated and largely opaque process. To navigate insurance hurdles, Calibrate built a proprietary Vertical Pharmacy Engine. The program supports members through a 52-week curriculum with 1:1 video coaching (rather than text bots) who help members standardized goals in food, sleep, exercise, and emotional health. Moreover, In an industry where 95% of diets fail, we build confidence and credibility through our results-based guarantee, informed by our members’ outcomes and promising a refund for eligible members who do not see a minimum of 10% weight loss within one year. This data demonstrates the power of our results over time, proving lasting and sustainable weight loss. We are committed to reporting our results annually and expanding upon evidence and reporting over time. By leveraging the proper medication for the appropriate amount of time in combination with effective ILI, we have a more profound and far-reaching health impact, and we create a path to continued health off of medication. We also contribute meaningfully to cost savings since these medications are more than $15,000 per year.
Validation
In the first 18 months in business, Calibrate released its Results Report that looked at 453 members at month 6 and 86 members at month 12. With this report, we've proven that Calibrate works with members experiencing an average of 15% weight loss. For context, the expectation of the best standard of care pre-Wegovy––a newly FDA-approved GLP-1 medication showing unprecedented results––was a 10% average weight loss. Our average of 15% weight loss is significant, highlighting the effectiveness and importance of our intensive lifestyle intervention used in combination with medication. Additionally, members saw an average 6.4 inch reduction in waist circumference which has a profound impact on one’s health. Waist circumference is a reflection of abdominal fat, and fat stored in the abdomen is much more inflammatory and associated with adverse effects of obesity. In addition, 75% of pre-diabetic members returned to normal HbA1C levels, showing an improvement in blood sugar that impacts both diabetes and other health conditions. Additionally 67% of members saw improvements in LDL cholesterol, 75% saw improvements in inflammation, 68% had reductions in fasting insulin, and 71% saw improvements in triglycerides.
